{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:30:18Z","timestamp":1786512618639,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["18\/0005865"],"award-info":[{"award-number":["18\/0005865"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["20\/0006297"],"award-info":[{"award-number":["20\/0006297"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["JDRF\/Lilly Diabetes Programme"],"award-info":[{"award-number":["JDRF\/Lilly Diabetes Programme"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King's Medical Research Trust PhD Studentship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Type 1 diabetes (T1D) is characterised by destruction of pancreatic beta-cells by islet-infiltrating cytotoxic lymphocytes and elevated intra-islet secretion of pro-inflammatory cytokines. However, the underlying pathophysiological mechanisms remain incompletely understood. We hypothesised that abnormal elevation of islet NAD, via activation of NAMPT, plays a key role in driving islet autoimmune processes, leading to beta-cell death in T1D. Here, we report that NAMPT inhibition protects against pro-inflammatory cytokine (IL-1\u03b2, TNF\u03b1 and IFN\u03b3) mediated beta-cell dysfunction and apoptosis in isolated mouse and human islets. RNAseq revealed that NAMPT inhibition blocked cytokine-mediated gene expression linked to pro-inflammatory responses and leukocyte migration. In vivo, diabetes was induced in CD1 mice via multiple low-dose streptozotocin (MLDS) injections. MLDS mice were administered the NAMPT inhibitor FK866 (10\u2009mg\/kg; IP) or saline equivalent for 16 days. These experiments demonstrated that NAMPT inhibition improved glycaemic control and beta-cell survival and function in MLDS mice. FK866 also reduced proportions of islet-residing TNF\u03b1-producing CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cells and F4\/80\n                    <jats:sup>+<\/jats:sup>\n                    macrophages, proliferation of spleen-derived CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cells and proliferation of islet-derived CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cells and F4\/80\n                    <jats:sup>+<\/jats:sup>\n                    macrophages. Finally, we report that NAMPT inhibition was able to block pro-inflammatory cytokine-mediated migration of cytotoxic CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cells into isolated islets, using an in vitro transwell platform. This data supports a key immunomodulatory role for NAMPT in islet autoimmunity. NAMPT inhibition may be able to prevent beta-cell death and thus represent a novel therapeutic approach for T1D. The effects of increased NAD levels on islet inflammation require in-depth characterisation and caution should be exercised with regard to the use of NAD boosting supplements, particularly in individuals at risk of developing T1D.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08700-6","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:05:10Z","timestamp":1780607110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in mice"],"prefix":"10.1038","volume":"17","author":[{"given":"Daniel","family":"Egbase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie R.","family":"Sayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-5449","authenticated-orcid":false,"given":"Naila","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesela S.","family":"Gesheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-1808","authenticated-orcid":false,"given":"Jithu J.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreya","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Kynaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella L.","family":"Hubber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna I. F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-5701","authenticated-orcid":false,"given":"Timothy J.","family":"Pullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1948-1960","authenticated-orcid":false,"given":"Yee","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Greally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Butterworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2867-2269","authenticated-orcid":false,"given":"James A.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin A.","family":"Bewick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta J.","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-0676","authenticated-orcid":false,"given":"Paul W.","family":"Caton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"8700_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1152\/physrev.00003.2010","volume":"91","author":"TL van Belle","year":"2011","unstructured":"van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91:79\u2013118.","journal-title":"Physiol Rev"},{"key":"8700_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.001","volume":"71","author":"NS Wilcox","year":"2016","unstructured":"Wilcox NS, Rui J, Hebrok M, Herold KC. Life and death of \u03b2 cells in Type 1 diabetes: a comprehensive review. J Autoimmun. 2016;71:51\u20138.","journal-title":"J Autoimmun"},{"key":"8700_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, Dabela D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016.","journal-title":"Nat Rev Dis Primers"},{"key":"8700_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142242","volume":"131","author":"AC Powers","year":"2021","unstructured":"Powers AC. Type 1 diabetes mellitus: much progress, many opportunities. J Clin Investig. 2021;131:e142242.","journal-title":"J Clin Investig"},{"key":"8700_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ng1323","volume":"36","author":"N Bottini","year":"2004","unstructured":"Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36:337\u20138.","journal-title":"Nat Genet"},{"key":"8700_CR6","doi-asserted-by":"publisher","first-page":"460S","DOI":"10.1093\/ajcn\/66.2.460S","volume":"66","author":"RK Chandra","year":"1997","unstructured":"Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr. 1997;66:460S\u2013463S.","journal-title":"Am J Clin Nutr"},{"key":"8700_CR7","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","volume":"57","author":"H Erlich","year":"2008","unstructured":"Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084\u201392.","journal-title":"Diabetes"},{"key":"8700_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/15209150050214122","volume":"2","author":"FR Kaufman","year":"2000","unstructured":"Kaufman FR. Role of the continuous glucose monitoring system in pediatric patients. Diabetes Technol Ther. 2000;2:49\u201352.","journal-title":"Diabetes Technol Ther"},{"key":"8700_CR9","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.2337\/db12-1398","volume":"62","author":"C Nguyen","year":"2013","unstructured":"Nguyen C, Varney MD, Harrison LC, Morahan G. Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms. Diabetes. 2013;62:2135\u201340.","journal-title":"Diabetes"},{"key":"8700_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/pedi.12388","volume":"17","author":"A Pugliese","year":"2016","unstructured":"Pugliese A. Insulitis in the pathogenesis of type 1 diabetes. Pediatr Diabetes. 2016;17:31\u201336.","journal-title":"Pediatr Diabetes"},{"key":"8700_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2337\/diabetes.53.1.113","volume":"53","author":"HE Thomas","year":"2004","unstructured":"Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, Allison J, et al. IL-1 Receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes. 2004;53:113\u201321.","journal-title":"Diabetes"},{"key":"8700_CR12","doi-asserted-by":"publisher","first-page":"13844","DOI":"10.1073\/pnas.94.25.13844","volume":"94","author":"B Wang","year":"1997","unstructured":"Wang B, Andr\u00e9 I, Gonzalez A, Katz JD, Aguet M, Benoist C, et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA. 1997;94:13844\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8700_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/01.mjt.0000178767.67857.63","volume":"12","author":"J-W Yoon","year":"2005","unstructured":"Yoon J-W, Jun H-S. Autoimmune destruction of pancreatic beta-cells. Am J Ther. 2005;12:580\u201391.","journal-title":"Am J Ther"},{"key":"8700_CR14","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","volume":"26","author":"PE Cryer","year":"2003","unstructured":"Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902\u201312.","journal-title":"Diabetes Care"},{"key":"8700_CR15","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.2337\/dc12-2109","volume":"36","author":"AM Jacobson","year":"2013","unstructured":"Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life. Diabetes Care. 2013;36:3131\u20138.","journal-title":"Diabetes Care"},{"key":"8700_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1900\/RDS.2012.9.385","volume":"9","author":"AMJ Shapiro","year":"2012","unstructured":"Shapiro AMJ. Islet Transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev Diabet Stud RDS. 2012;9:385\u2013406.","journal-title":"Rev Diabet Stud RDS"},{"key":"8700_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrendo.2016.178","volume":"13","author":"AMJ Shapiro","year":"2017","unstructured":"Shapiro AMJ, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017;13:268\u201377.","journal-title":"Nat Rev Endocrinol"},{"key":"8700_CR18","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2337\/db10-0103","volume":"59","author":"McCrimmonSherwin","year":"2010","unstructured":"McCrimmonSherwin. Hypoglycemia in type 1 diabetes. Diabetes. 2010;59:2333\u20139.","journal-title":"Diabetes"},{"key":"8700_CR19","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2337\/dc21-2482","volume":"45","author":"BA Pieri","year":"2022","unstructured":"Pieri BA, Bergin-Cartwright GAI, Simpson A, Collins J, Reid A, Karalliedde J, et al. Symptoms of anxiety and depression are independently associated with impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care. 2022;45:2456\u201360.","journal-title":"Diabetes Care"},{"key":"8700_CR20","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2337\/diabetes.48.10.1907","volume":"48","author":"W Bennet","year":"1999","unstructured":"Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999;48:1907\u201314.","journal-title":"Diabetes"},{"key":"8700_CR21","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Rammos","year":"2023","unstructured":"Rammos EL, Dayan CM, Chetenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and \u03b2-Cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389:2151\u201361.","journal-title":"N Engl J Med"},{"key":"8700_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrendo.2015.117","volume":"11","author":"A Garten","year":"2015","unstructured":"Garten A, Schuster S, Penke M, Gorski T, Giorgis T, de, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11:535\u201346.","journal-title":"Nat Rev Endocrinol"},{"key":"8700_CR23","first-page":"1","volume":"6","author":"LE Navas","year":"2021","unstructured":"Navas LE, Carnero A. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6:1\u201320.","journal-title":"Signal Transduct Target Ther"},{"key":"8700_CR24","doi-asserted-by":"publisher","first-page":"e2267.","DOI":"10.1371\/journal.pone.0002267","volume":"3","author":"N Busso","year":"2008","unstructured":"Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase\/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE. 2008;3:e2267.","journal-title":"PLoS ONE"},{"key":"8700_CR25","doi-asserted-by":"publisher","first-page":"259.","DOI":"10.3389\/fimmu.2013.00259","volume":"4","author":"IMA Ernst","year":"2013","unstructured":"Ernst IMA, Fliegert R, Guse AH. Adenine dinucleotide second messengers and t-lymphocyte calcium signaling. Front Immunol. 2013;4:259.","journal-title":"Front Immunol"},{"key":"8700_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bbamem.2013.07.009","volume":"1838","author":"N Joseph","year":"2014","unstructured":"Joseph N, Reicher B, Barda-Saad M. The calcium feedback loop and T cell activation: how cytoskeleton networks control intracellular calcium flux. Biochim Biophys Acta. 2014;1838:557\u201368.","journal-title":"Biochim Biophys Acta"},{"key":"8700_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1189\/jlb.0404262","volume":"77","author":"C Sandoval-Montes","year":"2005","unstructured":"Sandoval-Montes C, Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J Leukoc Biol. 2005;77:513\u201321.","journal-title":"J Leukoc Biol"},{"key":"8700_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12929","volume":"92","author":"DR Forsdyke","year":"2020","unstructured":"Forsdyke DR. Metabolic optimization of adoptive T cell transfer cancer immunotherapy: a historical overview. Scand J Immunol. 2020;92:e12929.","journal-title":"Scand J Immunol"},{"key":"8700_CR29","doi-asserted-by":"crossref","unstructured":"Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS ONE. 2009;4:e7897.","DOI":"10.1371\/journal.pone.0007897"},{"key":"8700_CR30","doi-asserted-by":"crossref","unstructured":"Al-Shabany AJ, Moody AJ, Foey AD, Billington RA. Intracellular NAD+ levels are associated with LPS-induced TNF-\u03b1 release in pro-inflammatory macrophages. Biosci Rep. 2016;36:e00301.","DOI":"10.1042\/BSR20150247"},{"key":"8700_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41590-019-0336-y","volume":"ume 20","author":"AM Cameron","year":"2019","unstructured":"Cameron AM, Castoldi A, Sanin DE, Flachsmann LJ, Field CS, Puleston DJ, et al. Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species\u2013mediated DNA damage. Nat Immunol. 2019;ume 20:420\u201332.","journal-title":"Nat Immunol"},{"key":"8700_CR32","doi-asserted-by":"publisher","first-page":"e97378","DOI":"10.1371\/journal.pone.0097378","volume":"9","author":"G Venter","year":"2014","unstructured":"Venter G, Oerlemans FTJJ, Willemse M, Wijers M, Fransen JAM, Wieringa B. NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages. PLoS ONE. 2014;9:e97378.","journal-title":"PLoS ONE"},{"key":"8700_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/gutjnl-2017-314241","volume":"67","author":"RR Gerner","year":"2018","unstructured":"Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2018;67:1813\u201323.","journal-title":"Gut"},{"key":"8700_CR34","doi-asserted-by":"crossref","unstructured":"Tullius SG, Biefer HRC, Li S, Trachtenberg AJ, Edtinger K, Quante M. NAD+ protects against EAE by regulating CD4+ T-cell differentiation. Nat Commun. 2014;5:5101.","DOI":"10.1038\/ncomms6101"},{"key":"8700_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109516","volume":"36","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang F, Wang L, Qiu S, Yao Y, Yan C, et al. NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell Rep. 2021;36:109516.","journal-title":"Cell Rep"},{"key":"8700_CR36","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.3390\/ijms22136860","volume":"22","author":"L Mercurio","year":"2021","unstructured":"Mercurio L, Morelli M, Scarponi C, Scaglione GL, Pallotta S, Avitabile D, et al. Enhanced NAMPT-mediated NAD Salvage pathway contributes to psoriasis pathogenesis by amplifying epithelial auto-inflammatory circuits. Int J Mol Sci. 2021;22:6860.","journal-title":"Int J Mol Sci"},{"key":"8700_CR37","doi-asserted-by":"publisher","first-page":"119188","DOI":"10.1016\/j.atherosclerosis.2025.119188","volume":"404","author":"YJ Wang","year":"2025","unstructured":"Wang YJ, Gaul DS, Gorica E, Pahla J, Wang Z, Mohammed SA, et al. NAD+ boosting increases atherosclerotic plaques and inflammation in Apoe knockout mice. Atherosclerosis. 2025;404:119188.","journal-title":"Atherosclerosis"},{"key":"8700_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41591-023-02793-8","volume":"30","author":"M Ferrell","year":"2024","unstructured":"Ferrell M, Wang Z, Anderson JT, Li XS, Witkowski M, DiDonato JA, et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med. 2024;30:424\u201334.","journal-title":"Nat Med"},{"key":"8700_CR39","first-page":"7436","volume":"63","author":"M Hasmann","year":"2003","unstructured":"Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63:7436\u201342.","journal-title":"Cancer Res"},{"key":"8700_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nsmb1105","volume":"13","author":"JA Khan","year":"2006","unstructured":"Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006;13:582\u20138.","journal-title":"Nat Struct Mol Biol"},{"key":"8700_CR41","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1016\/j.bmcl.2013.04.040","volume":"ume 23","author":"J Gunzner-Toste","year":"2013","unstructured":"Gunzner-Toste J, Zhao G, Bauer P, Baumeister T, Buckmelter AJ, Caligiuri M, et al. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. Bioorg Med Chem Lett. 2013;ume 23:3531\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"8700_CR42","doi-asserted-by":"crossref","unstructured":"Pavlovic S, Petrovic I, Jovicic N, Ljujic B, Miletic Kovacevic M, Arsenijevic N, et al. IL-33 prevents MLD-STZ induction of diabetes and attenuate insulitis in prediabetic NOD mice. Front Immunol 2018;9:264.","DOI":"10.3389\/fimmu.2018.02646"},{"key":"8700_CR43","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1096\/fba.2019-00031","volume":"1","author":"Z Luo","year":"2019","unstructured":"Luo Z, Solang C, Mejia-Cordova M, Thorvaldson L, Blixt M, Sandler S, et al. Kinetics of immune cell responses in the multiple low-dose streptozotocin mouse model of type 1 diabetes. FASEB BioAdvances. 2019;1:538\u201349.","journal-title":"FASEB BioAdvances"},{"key":"8700_CR44","volume":"2021","author":"K Lin","year":"2021","unstructured":"Lin K, Yang X, Wu Y, Chen S, Zeng Q. Residual \u03b2-cell function in type 1 diabetes followed for 2 years after 3C study. J Diabetes Res. 2021;2021:e9946874.","journal-title":"J Diabetes Res"},{"key":"8700_CR45","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.2337\/dc13-0418","volume":"36","author":"JS S\u00f8rensen","year":"2013","unstructured":"S\u00f8rensen JS, Johannesen J, Pociot F, Kristensen K, Thomsen J, Hertel NT, et al. Residual \u03b2-cell function 3\u20136 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care. 2013;36:3454\u20139.","journal-title":"Diabetes Care"},{"key":"8700_CR46","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/414792a","volume":"414","author":"D Mathis","year":"2001","unstructured":"Mathis D, Vence L, Benoist C. \u03b2-Cell death during progression to diabetes. Nature. 2001;414:792\u20138.","journal-title":"Nature"},{"key":"8700_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1749-6632.2012.06826.x","volume":"1281","author":"LE Padgett","year":"2013","unstructured":"Padgett LE, Broniowska KA, Hansen PA, Corbett JA, Tse HM. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci. 2013;1281:16\u201335.","journal-title":"Ann N Y Acad Sci"},{"key":"8700_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/18024","volume":"398","author":"AH Guse","year":"1999","unstructured":"Guse AH, da Silva CP, Berg I, Skapenko AL, Weber K, Heyer P, et al. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature. 1999;398:70\u201373.","journal-title":"Nature"},{"key":"8700_CR49","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1096\/fasebj.12.7.581","volume":"12","author":"M Morra","year":"1998","unstructured":"Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F. CD38 is functionally dependent on the TCR\/CD3 complex in human T cells. FASEB J. 1998;12:581\u201392.","journal-title":"FASEB J"},{"key":"8700_CR50","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s00125-011-2288-0","volume":"54","author":"PW Caton","year":"2011","unstructured":"Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia. 2011;54:3083\u201392.","journal-title":"Diabetologia"},{"key":"8700_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cmet.2007.09.003","volume":"6","author":"JR Revollo","year":"2007","unstructured":"Revollo JR, K\u00f6rner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt\/PBEF\/visfatin regulates insulin secretion in \u03b2 cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363\u201375.","journal-title":"Cell Metab"},{"key":"8700_CR52","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00125-016-4076-3","volume":"59","author":"J Kieswich","year":"2016","unstructured":"Kieswich J, Sayers SR, Silvestre MF, Harwood SM, Yaqoob MM, Caton PW. Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment. Diabetologia. 2016;59:2477\u201386.","journal-title":"Diabetologia"},{"key":"8700_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00125-019-05029-y","volume":"63","author":"SR Sayers","year":"2020","unstructured":"Sayers SR, Beavil RL, Fine NHF, Huang GC, Choudhary P, Pacholarz KJ, et al. Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta-cell dysfunction in type 2 diabetes. Diabetologia. 2020;63:313\u201323.","journal-title":"Diabetologia"},{"key":"8700_CR54","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1158\/1078-0432.CCR-14-0624","volume":"20","author":"I Gehrke","year":"2014","unstructured":"Gehrke I, Bouchard EDJ, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, et al. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clin Cancer Res. 2014;20:4861\u201372.","journal-title":"Clin Cancer Res"},{"key":"8700_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-01007-3","volume":"8","author":"T Nishida","year":"2022","unstructured":"Nishida T, Naguro I, Ichijo H. NAMPT-dependent NAD+ salvage is crucial for the decision between apoptotic and necrotic cell death under oxidative stress. Cell Death Discov. 2022;8:1\u201311.","journal-title":"Cell Death Discov"},{"key":"8700_CR56","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.bcp.2009.02.017","volume":"77","author":"L Formentini","year":"2009","unstructured":"Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol. 2009;77:1612\u201320.","journal-title":"Biochem Pharmacol"},{"key":"8700_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ab.2010.12.035","volume":"412","author":"R-Y Zhang","year":"2011","unstructured":"Zhang R-Y, Qin Y, Lv X-Q, Wang P, Xu T-Y, Zhang L, et al. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. Anal Biochem. 2011;412:18\u201325.","journal-title":"Anal Biochem"},{"key":"8700_CR58","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1042\/bj2540397","volume":"254","author":"PM Jones","year":"1988","unstructured":"Jones PM, Salmon DM, Howell SL. Protein phosphorylation in electrically permeabilized islets of Langerhans. Effects of Ca2+, cyclic AMP, a phorbol ester and noradrenaline. Biochem J. 1988;254:397\u2013403.","journal-title":"Biochem J"},{"key":"8700_CR59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.TP.0000100401.62912.B2","volume":"77","author":"GC Huang","year":"2004","unstructured":"Huang GC, Zhao M, Jones P, Persaud S, Ramracheya R, L\u00f6bner K, et al. The development of new density gradient media for purifying human islets and islet-quality assessments. Transplantation. 2004a;77:143\u20135.","journal-title":"Transplantation"},{"key":"8700_CR60","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41420-024-02234-6","volume":"10","author":"N Haq","year":"2024","unstructured":"Haq N, Toczyska KW, Wilson ME, Jacobs M, Zhao Min, Lei Y, et al. Reformed islets: a long-term primary cell-based platform for exploring mouse and human islet biology. Cell Death Discov. 2024;10:480.","journal-title":"Cell Death Discov"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08700-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08700-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08700-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:02:52Z","timestamp":1786510972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08700-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8700"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08700-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"713"}}